RRM2 and ovarian carcinoma: Liu et al. (2019) reported increased RRM2 mRNA expression in peripheral blood samples from patients resistant to imatinib. Therefore, RRM2 has the potential to serve as a biomarker and has already been used as a therapeutic target for chemotherapy. As one of the RRM2 inhibitors, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) has the potential to restore sensitivity to platinum-based treatment in cases of platinum-resistant ovarian cancer (Kunos et al., 2012).